A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer - GeparQuinto

Trial Profile

A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer - GeparQuinto

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary) ; Lapatinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Paclitaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms GeparQuinto
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 13 May 2016 Results of pooled sub-group analysis assessing PIK3CA mutations from GeparQuattro, GeparQuinto, GeparSixto, NeoALTTO and CHERLOB trials (n=967) published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top